Expanding the diversity of allosteric Bcr-Abl inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 19, 2010, Pages 6934-6946

  Deng, Xianming ^a,b   Okram, Barun ^c   Ding, Qiang ^d   Zhang, Jianming ^a,b   Choi, Yongmun ^a,b   Adrián, Francisco J ^d   Wojciechowski, Amy ^a,b   Zhang, Guobao ^d   Che, Jianwei ^d   Bursulaya, Badry ^d   Cowan Jacob, Sandra W ^e   Rummel, Gabriele ^e   Sim, Taebo ^f   Gray, Nathanael S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (PYRIDIN 3 YLMETHYL) N (4 (TRIFLUOROMETHOXY)PHENYL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 2 (PYRIDIN 3 YLMETHYL) N (4 (TRIFLUOROMETHOXY)PHENYL) 2H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 2 [4 (4 (TRILFUOROMETHOXY)PHENYLAMINO) 1H PYRRAZO [3,4 D]PYRIMIDIN 1 YL]ETHANOL; 2 [4 (4 (TRILFUOROMETHOXY)PHENYLAMINO) 2H PYRRAZO [3,4 D]PYRIMIDIN 2 YL]ETHANOL; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; METHYL 4 (4 (TRILFUOROMETHOXY) PHENYLAMINO)THIENO[2,3 D]PYRIMIDINE 6 CARBOXYLATE; MYRISTIC ACID; N (2 HYDROXYETHYL) 3 (6 (4 (TRIFLUOROMETHOXY)PHENYLAMINO)PYRIMIDIN 4 YL)BENZAMIDE; N (2 HYDROXYETHYL) 4 (4 (TRILFUOROMETHOXY)PHENYLAMINO)THIENO[2,3 D]PYRIMIDINE 6 CARBOXAMIDE; N (3 METHOXYPROPYL) 3 [4 (4 (TRILFUOROMETHOXY)PHENYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL]PROPANAMIDE; N 4 (3 MORPHOLINOPROPYL) N 6 (4 (TRIFLUOROMETHOXY)PHENYL)PYRIMIDINE 4,6 DIAMINE; N(4 (TRILFUOROMETHOXY)PHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; PROTEIN KINASE INHIBITOR; THIENO[2,3 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; MOUSE; MUTATION; SYNTHESIS; TRANSFORMED CELL LINE;

ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TRANSFORMED; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; MICE; MODELS, MOLECULAR; MUTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 77957930406     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100555f     Document Type: Article

References (31)

1. Faderl, S.; Kantarjian, H. M.; Talpaz, M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park, N.Y.) 1999, 13, 169 - 80; discussion 181, 184.
2. Cowan-Jacob, S. W.; Guez, V.; Fendrich, G.; Griffin, J. D.; Fabbro, D.; Furet, P.; Liebetanz, J.; Mestan, J.; Manley, P. W. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment Mini-Rev. Med. Chem. 2004, 4, 285-299
3. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7, 129-141
4. Manley, P. W.; Cowan-Jacob, S. W.; Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Biochim. Biophys. Acta 2005, 1754, 3-13
5. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N -(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 2004, 47, 6658-6661
6. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor Science 2004, 305, 399-401
7. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Jia, T.; Manley, P. W.; Mestan, J.; Cowan-Jacob, S. W.; Lee, F. Y.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res. 2005, 65, 4500-4505
8. Adrian, F. J.; Ding, Q.; Sim, T.; Velentza, A.; Sloan, C.; Liu, Y.; Zhang, G.; Hur, W.; Ding, S.; Manley, P.; Mestan, J.; Fabbro, D.; Gray, N. S. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation Nat. Chem. Biol. 2006, 2, 95-102
9. Zhang, J.; Adrian, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G. R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 2010, 463, 501-506
10. Ding, S.; Gray, N. S.; Wu, X.; Ding, Q.; Schultz, P. G. A combinatorial scaffold approach toward kinase-directed heterocycle libraries J. Am. Chem. Soc. 2002, 124, 1594-1596
11. Liu, J.; Wu, X.; Mitchell, B.; Kintner, C.; Ding, S.; Schultz, P. G. A small-molecule agonist of the Wnt signaling pathway Angew. Chem., Int. Ed. 2005, 44, 1987-1990
12. Zhang, Q.; Liu, Y.; Gao, F.; Ding, Q.; Cho, C.; Hur, W.; Jin, Y.; Uno, T.; Joazeiro, C. A.; Gray, N. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library J. Am. Chem. Soc. 2006, 128, 2182-2183
13. Manley, P. J; Balitza, A. E; Bilodeau, M. T.; Coll, K. E; Hartman, G. D.; McFall, R. C.; Rickert, K. W.; Rodman, L. D.; Thomas, K. A. 2,4-Disubstituted pyrimidines: a novel class of KDR kinase inhibitors Bioorg. Med. Chem. Lett. 2003, 13, 1673-1677
14. Beattie, J. F.; Breault, G. A.; Ellston, R. P.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: Identification and optimisation of substituted 4,6-bis anilino pyrimidines Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960 (Pubitemid 36993619)
15. Miyaura, N. Top. Curr. Chem. 2002, 219, 11-59
16. Muci, A. R.; Buchwald, S. L. Top. Curr. Chem. 2002, 219, 131-209
17. Suzuki, A. Modern Arene Chemistry; Astruc, D., Ed.; Wiley-VCH: Weinheim, Germany, 2002; pp 53 - 106.
18. Hartwig, J. F. Modern Arene Chemistry; Astruc, D., Ed.; Wiley-VCH: Weinheim, Germany, 2002; pp 107 - 168.
19. Luesch, H.; Wu, T. Y.; Ren, P.; Gray, N. S.; Schultz, P. G.; Supek, F. A genome-wide overexpression screen in yeast for small-molecule target identification Chem. Biol. 2005, 12, 55-63
20. Glide, version 2.5; Schrödinger, L.L.C.: New York. The Glide 2.5 calculations used FirstDiscovery, version 2.5021, which was released in June 2003.
21. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
22. Li, Y.; Xie, W.; Fang, G. Fluorescence detection techniques for protein kinase assay Anal. Bioanal. Chem. 2008, 390, 2049-2057
23. Corbin, A. S.; La Rosee, P.; Stoffregen, E. P.; Druker, B. J.; Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood 2003, 101, 4611-4614
24. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
25. Ziegler, W. H.; Tigges, U.; Zieseniss, A.; Jockusch, B. M. A lipid-regulated docking site on vinculin for protein kinase C J. Biol. Chem. 2002, 277, 7396-7404
26. Fang, Y.; Vilella-Bach, M.; Bachmann, R.; Flanigan, A.; Chen, J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling Science 2001, 294, 1942-1945
27. Hantschel, O.; Nagar, B.; Guettler, S.; Kretzschmar, J.; Dorey, K.; Kuriyan, J.; Superti-Furga, G. A myristoyl/phosphotyrosine switch regulates c-Abl Cell 2003, 112, 845-857
28. Delon, C.; Manifava, M.; Wood, E.; Thompson, D.; Krugmann, S.; Pyne, S.; Ktistakis, N. T. Sphingosine kinase 1 is an intracellular effector of phosphatidic acid J. Biol. Chem. 2004, 279, 44763-44774
29. Castillo, S. S.; Brognard, J.; Petukhov, P. A.; Zhang, C.; Tsurutani, J.; Granville, C. A.; Li, M.; Jung, M.; West, K. A.; Gills, J. G.; Kozikowski, A. P.; Dennis, P. A. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues Cancer Res. 2004, 64, 2782-2792
30. Azam, M.; Latek, R. R.; Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 2003, 112, 831-843
31. Structure assignment was according to the reported analogs. See the following: Da Settimo, F.; Primofiore, G.; La Motta, C.; Taliani, S.; Simorini, F.; Marini, A. M.; Mugnaini, L.; Lavecchia, A.; Novellino, E.; Tuscano, D.; Martini, C. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4- d ]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies J. Med. Chem. 2005, 48, 5162-5174